Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Current Value
$0.691 Year Return
Current Value
$0.691 Year Return
Market Cap
$10.02M
P/E Ratio
-0.37
1Y Stock Return
-22.89%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
1.2
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
QSR | <0.01% | $22.48B | -1.07% | 3.30% |
STAA | 0.01% | $1.29B | -22.11% | 0.00% |
BY | 0.02% | $1.36B | +51.33% | 1.18% |
KOD | 0.02% | $296.80M | +150.67% | 0.00% |
TCOM | -0.02% | $40.41B | +91.40% | 0.00% |
REPX | 0.02% | $745.24M | +32.40% | 4.19% |
VRDN | -0.02% | $1.60B | +28.92% | 0.00% |
JCI | -0.02% | $55.80B | +59.01% | 1.77% |
TME | -0.02% | $7.80B | +28.31% | 1.22% |
SCHL | -0.03% | $682.89M | -38.46% | 3.31% |
ALG | 0.03% | $2.30B | +4.01% | 0.55% |
OPRT | -0.03% | $112.95M | +40.81% | 0.00% |
WRBY | -0.03% | $2.75B | +120.67% | 0.00% |
SSYS | -0.03% | $647.34M | -15.06% | 0.00% |
OSIS | 0.03% | $2.57B | +29.40% | 0.00% |
MTDR | -0.03% | $7.21B | -1.21% | 1.47% |
AGR | -0.04% | $13.92B | +15.51% | 4.90% |
AADI | -0.04% | $54.47M | -52.78% | 0.00% |
KLG | 0.04% | $1.48B | +45.15% | 3.71% |
SLP | 0.04% | $554.26M | -28.05% | 0.66% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ROIC | 63.21% | $2.22B | +43.52% | 3.45% |
PLOW | 46.82% | $572.50M | -7.57% | 4.79% |
FFIV | 43.69% | $13.97B | +44.43% | 0.00% |
CVLT | 43.66% | $7.37B | +136.34% | 0.00% |
VRNS | 40.50% | $5.57B | +25.45% | 0.00% |
HSII | 39.79% | $914.74M | +64.66% | 1.35% |
SEG | 37.01% | $319.72M | +12.41% | 0.00% |
HWM | 36.18% | $47.13B | +122.99% | 0.22% |
SFM | 34.47% | $14.34B | +254.87% | 0.00% |
HLIT | 33.08% | $1.42B | +12.53% | 0.00% |
RGEN | 26.56% | $7.20B | -18.16% | 0.00% |
COLL | 26.45% | $959.44M | +16.71% | 0.00% |
KRG | 26.12% | $6.01B | +34.05% | 3.71% |
HAYW | 25.99% | $3.43B | +37.45% | 0.00% |
CHCT | 25.26% | $527.85M | -29.47% | 9.98% |
BFS | 24.23% | $968.52M | +11.80% | 5.92% |
PECO | 24.12% | $4.81B | +11.44% | 3.04% |
PCH | 23.90% | $3.28B | -11.32% | 4.36% |
CBZ | 22.98% | $3.87B | +33.45% | 0.00% |
STRA | 22.32% | $2.33B | +6.80% | 2.53% |
Yahoo
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Preparations Underway for Phase 3 Ovarian Cancer Trial; Set to Initiate in 1Q25 Imunon, Inc. (NASDAQ:IMNN) previously reported positive topline results from the Phase 2 OVATION 2 trial of IMNN-001 in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. IMNN-001 is
Yahoo
Imunon Inc (IMNN) reports significant progress in ovarian cancer treatment trials, while navigating increased R&D expenses and funding needs.
SeekingAlpha
Imunon, Inc. (NASDAQ:IMNN) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ETCompany ParticipantsKim Golodetz - Alliance Advisors IRStacy...
Yahoo
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was generally well tolerated, with no reports of cytokine release syndrome or any other serious immune related adverse events Company plans to initiate Phase 3 pivotal trial of IMNN-001 in Q1 2025 LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company
Yahoo
Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three and nine months ended September 30, 2024. The Company also provided an update on its clinical development of IMNN-001 including progress toward commencing a Phase 3 study in advanced ovarian cancer, and an update on IMNN-101, its seasonal COV
Yahoo
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunoth
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
WWD | -49.46% | $10.19B | +29.97% | 0.44% |
AMKR | -34.16% | $6.26B | -6.38% | 1.25% |
MRK | -31.26% | $244.21B | -5.55% | 3.18% |
ECL | -30.63% | $69.18B | +30.92% | 0.93% |
LTC | -26.74% | $1.75B | +19.49% | 5.93% |
MBIN | -26.22% | $1.78B | +16.49% | 0.90% |
QXO | -25.89% | $6.51B | -35.95% | 0.00% |
PG | -24.35% | $402.15B | +14.14% | 2.33% |
TLK | -23.38% | $16.88B | -27.18% | 6.58% |
SYM | -21.80% | $4.05B | -25.08% | 0.00% |
GLW | -20.13% | $40.49B | +68.23% | 2.37% |
GEV | -20.01% | $93.72B | +159.05% | 0.00% |
TRS | -19.53% | $1.06B | +9.03% | 0.61% |
RMBS | -18.24% | $5.57B | -21.87% | 0.00% |
BMO | -17.49% | $68.63B | +16.42% | 4.74% |
LITB | -17.29% | $35.48M | -75.45% | 0.00% |
CAMT | -17.22% | $3.40B | +16.39% | 0.00% |
PSN | -17.16% | $10.03B | +50.06% | 0.00% |
NVAX | -16.98% | $1.28B | +49.53% | 0.00% |
NVDA | -16.87% | $3.61T | +194.35% | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EDV | -<0.01% | $3.88B | 0.06% |
SPTL | 0.01% | $10.33B | 0.03% |
VRP | -0.01% | $1.83B | 0.5% |
BSCW | 0.02% | $635.46M | 0.1% |
FLRN | 0.02% | $2.33B | 0.15% |
KWEB | -0.03% | $5.94B | 0.7% |
IEF | -0.03% | $32.30B | 0.15% |
SCHR | -0.03% | $9.97B | 0.03% |
WEAT | 0.03% | $120.27M | 0.28% |
DWX | -0.04% | $403.50M | 0.45% |
NUAG | -0.04% | $37.49M | 0.21% |
PFFV | 0.04% | $257.84M | 0.25% |
IBDR | 0.04% | $2.93B | 0.1% |
AOK | -0.04% | $617.23M | 0.15% |
OWNS | 0.05% | $124.17M | 0.3% |
DMXF | 0.06% | $761.60M | 0.12% |
BLV | -0.06% | $5.68B | 0.04% |
FXI | 0.06% | $8.09B | 0.74% |
IDRV | 0.06% | $180.64M | 0.47% |
BSJP | 0.09% | $1.00B | 0.42% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JUCY | -16.08% | $324.29M | 0.6% |
SMH | -11.72% | $23.66B | 0.35% |
FTXL | -11.31% | $1.31B | 0.6% |
KCCA | -11.14% | $220.51M | 0.87% |
PSI | -11.10% | $711.93M | 0.56% |
SOYB | -10.85% | $27.32M | 0.22% |
XLK | -10.43% | $71.43B | 0.09% |
SOXQ | -10.27% | $490.35M | 0.19% |
IXN | -9.83% | $5.14B | 0.41% |
QYLD | -9.59% | $8.25B | 0.61% |
QQA | -9.57% | $135.01M | 0% |
HIGH | -9.37% | $302.78M | 0.51% |
FFOG | -9.34% | $118.40M | 0.55% |
SPMO | -9.23% | $3.92B | 0.13% |
JEPQ | -9.09% | $18.60B | 0.35% |
SOXX | -9.08% | $13.20B | 0.35% |
VOOG | -8.91% | $13.96B | 0.1% |
IWY | -8.81% | $12.45B | 0.2% |
JGRO | -8.41% | $3.98B | 0.44% |
FTEC | -8.40% | $12.59B | 0.084% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BILZ | 36.89% | $563.02M | 0.14% |
KIE | 15.78% | $956.77M | 0.35% |
XMLV | 14.74% | $976.94M | 0.25% |
RSPH | 14.32% | $885.96M | 0.4% |
FTA | 13.81% | $1.27B | 0.6% |
FXG | 13.56% | $393.25M | 0.63% |
HDV | 13.01% | $11.19B | 0.08% |
PWV | 12.80% | $1.01B | 0.53% |
IAK | 12.76% | $760.79M | 0.39% |
FDL | 12.52% | $4.50B | 0.45% |
IHF | 12.20% | $703.90M | 0.4% |
SMOT | 12.19% | $374.04M | 0.49% |
PBJ | 12.19% | $109.21M | 0.62% |
RSPF | 12.07% | $311.69M | 0.4% |
RPV | 12.06% | $2.09B | 0.35% |
LVHD | 11.99% | $560.70M | 0.27% |
SCHD | 11.99% | $65.70B | 0.06% |
PBDC | 11.74% | $114.81M | 13.94% |
FREL | 11.46% | $1.06B | 0.084% |
XLF | 11.45% | $50.48B | 0.09% |